Indeed, results from the FLEX trial demonstrate that cetuximab in combination with ... on personalized cancer care in the context of KRAS mutation status in colorectal cancer, the clinical ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

and rash (2.1% each). Kopetz said the global phase III, randomized KRYSTAL-10 trial has completed enrollment and will compare the combination of adagrasib and cetuximab versus FOLFIRI or mFOLFOX6 ...

The therapy combines Krazati (adagrasib) and cetuximab and is approved for patients ... The approved combination targets a specific mutation in the KRAS gene, known as G12C. This mutation is ...

However, the most commonly observed KRAS mutations are KRAS-G12D and KRAS-G12V, highlighting the need for developing therapies that can specifically target other RAS-mutations and/or a therapy ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.